Clinical trials: neoadjuvant therapy, completed
Pancreatic Cancer
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00089024
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Breast Cancer
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499083
- Testing
- therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Colon Cancer, Primary Tumour
The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer
The clinical benefit of resection of the primary tumour in patients with synchronous unresectable metastases is not known. In the literature studies usually describe retrospective selected patients with synchronous metastases…
- Conditions
- Colon Cancer, Primary Tumour, Rectal Cancer
- Trial name
- CAIRO4 (NCT01606098)
- Testing
- Surgery of the primary tumour, Systemic treatment
- Where
- 46 sites in Denmark, Netherlands
- Volunteers
- 206 people
- Sponsor
- Dutch Colorectal Cancer Group
Bladder Cancer, Urothelial Carcinoma
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer
- Trial name
- NCT03636256
- Testing
- NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- NanOlogy, LLC
Prostate Cancer
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as flutamide and buserelin may stop the adrenal glands from producing androgens.
- Trial name
- NCT00054106
- Testing
- buserelin, custirsen sodium, flutamide
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- NCIC Clinical Trials Group
Sarcoma
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006734
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 239 sites in United States, Australia and 5 more
- Volunteers
- 587 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Luteinizing hormone-releasing hormone agonists may lessen the amount of androgens made by the body.
- Trial name
- SHIP0804 (NCT00664456)
- Testing
- Adjuvant therapy, Neoadjuvant therapy, Brachytherapy（iodine I 125）
- Where
- Japan
- Volunteers
- 421 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Lung Adenocarcinoma
Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1002. The study is a prospective, single-center, open-label, single-armed, phase II clinical trial.
- Trial name
- NCT02980991
- Testing
- Pemetrexed, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Pancreatic Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00049348
- Testing
- epoetin alfa, filgrastim, cisplatin
- Where
- 137 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Anesthesia; Adverse Effect
Different Anesthetic Technique For ERCP
Providing the appropriate anesthetic technique for endoscopic retrograde cholangiopancreatography (ERCP) in remote locations can be challenging.
- Trial name
- NCT04087668
- Testing
- Monitored Anesthesia Care, General Anesthesia, Induction Without Neuromuscular Blockade
- Where
- China
- Volunteers
- 405 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00881361
- Testing
- systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy
- Where
- 324 sites in United States
- Volunteers
- 756 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rectal Cancer
Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer
The purpose of this study is to establish the influence of time-interval between preoperative hyperfractionated radiotherapy (5x5 Gy) and surgery on long term overall survival (5 years), local and distant recurrence rate…
- Trial name
- NCT01444495
- Testing
- Preoperative radiotherapy, Surgery
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Jagiellonian University
High-Grade Upper Tract Urothelial Carcinoma
Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC
The purpose of this study is to see if getting chemotherapy with Gemcitabine and Cisplatin (GC) for 2-4 cycles can help shrink the tumor before undergoing surgery and improves the overall survival for high-grade upper tract…
- Trial name
- NCT02876861
- Testing
- Radical nephroureterectomy, Distal ureterectomy, Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Xiangya Hospital of Central South University
Colorectal Adenocarcinoma
Oncological Impact of Lateral Nodes in Rectal Cancer
The combination of neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) is considered the standard treatment for locally advanced rectal cancer in the western world.
- Trial name
- I-ONARC (NCT05592873)
- Testing
- Neoadjuvant chemoradiotherapy (CRT)
- Volunteers
- 317 people
- Sponsor
- Niguarda Hospital
Rectal Cancer
Surgery Alone Versus Neoadjuvant Treatment Followed by Surgery For MRI-defined T3 Mid-low Rectal Cancer
Neoadjuvant treatments (nCRT) are becoming the standard treatment for patients with stage II or stage III mid-low rectal cancer.
- Trial name
- NCT05496270
- Testing
- total mesorectal excision
- Volunteers
- 1,509 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Non-Small-Cell Lung Cancer
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
Open-label multicenter randomized Phase III trial.
- Trial name
- NATCH (NCT00913705)
- Testing
- Neoadjuvant chemotherapy (taxol and carboplatin), Adjuvant chemotherapy (taxol and carboplatin), Surgery
- Volunteers
- 624 people
- Sponsor
- Spanish Lung Cancer Group
Cervix Cancer, Cervical Cancer
Neoadjuvant Chemotherapy in Cervical Cancer
Cervical cancer represents the second commonest cancer in women worldwide, with 500,000 new cases and 300,000 deaths reported yearly.
- Conditions
- Cervix Cancer, Cervical Cancer, Cancer of the Uterine Cervix
- Trial name
- NCT05384366
- Testing
- Neoadjuvant chemotherapy
- Where
- India
- Volunteers
- 33 people
- Sponsor
- Banaras Hindu University
Bowel; Functional Syndrome, Rectal Cancer
Long Term Bowel Function Following Rectal Cancer Surgery
In this longitudinal study, 171 patients were evaluated and compared based on the radiation therapy they received. Bowel function was assessed longitudinally with Memorial Sloan Kettering Cancer Center and Wexner scores every 6…
- Trial name
- NCT05339763
- Testing
- chemoradiotherapy
- Where
- Egypt
- Volunteers
- 171 people
- Sponsor
- Mansoura University
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.